Loading
companiesCompany
Jeito Capital
Jeito Capital is a Paris fund that writes large cheques for European biotech companies so they can take drugs through late-stage trials without selling early. Cancer medicines are a recurring theme.
Overview
Jeito Capital is a Paris-based growth-stage life-science investor founded in 2018 by Rafaele Tordjman, with a stated focus on patient benefit and on giving European biopharma companies the capital to run pivotal programmes and build commercial capabilities in Europe rather than out-licensing early. It participates in and leads large Series B and C rounds, several of them in oncology; the portfolio links in OnCo are derived from the startup records that name it.
Portfolio (4)
Filter the startups table| Company | Stage | Type | Cancers | Latest round |
|---|---|---|---|---|
| Adcendo Copenhagen, DK | Growth stage | biotech | Sarcomas (soft tissue, bone, GIST) | Series C 2026, $75M |
| Alentis Therapeutics Basel, CH | Growth stage | biotech | Series D 2024, $181M | |
| Callio Therapeutics Seattle, WA, US | Startup | biotech | HER2-positive breast cancer | Series A 2025, $187M |
| Neogene Therapeutics Amsterdam, NL | Acquired | cell therapy | Acquisition 2023, $320M |
Similar pages
- CompanyNovo Holdings
Shares Alentis Therapeutics, Callio Therapeutics, Adcendo and the tag vc.
- CompanyOrbiMed
Shares Alentis Therapeutics, Adcendo and the tag vc.
- CompanyVida Ventures
Shares Neogene Therapeutics, Adcendo and the tag vc.
- CompanyEcoR1 Capital
Shares Neogene Therapeutics and the tag vc.
- CompanyFrazier Life Sciences
Shares Alentis Therapeutics, Callio Therapeutics and the tag vc.
- CompanyPolaris Partners
Shares Neogene Therapeutics and the tag vc.
- CompanyGilde Healthcare
Shares Adcendo and the tag vc.
- CompanyRA Capital Management
Shares Alentis Therapeutics, Adcendo and the tag vc.